Stabilizing ER Ca2+ Channel Function as an Early Preventative Strategy for Alzheimer’s Disease
Open Access
- 21 December 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (12), e52056
- https://doi.org/10.1371/journal.pone.0052056
Abstract
Alzheimer’s disease (AD) is a devastating neurodegenerative condition with no known cure. While current therapies target late-stage amyloid formation and cholinergic tone, to date, these strategies have proven ineffective at preventing disease progression. The reasons for this may be varied, and could reflect late intervention, or, that earlier pathogenic mechanisms have been overlooked and permitted to accelerate the disease process. One such example would include synaptic pathology, the disease component strongly associated with cognitive impairment. Dysregulated Ca2+ homeostasis may be one of the critical factors driving synaptic dysfunction. One of the earliest pathophysiological indicators in mutant presenilin (PS) AD mice is increased intracellular Ca2+ signaling, predominantly through the ER-localized inositol triphosphate (IP3) and ryanodine receptors (RyR). In particular, the RyR-mediated Ca2+ upregulation within synaptic compartments is associated with altered synaptic homeostasis and network depression at early (presymptomatic) AD stages. Here, we offer an alternative approach to AD therapeutics by stabilizing early pathogenic mechanisms associated with synaptic abnormalities. We targeted the RyR as a means to prevent disease progression, and sub-chronically treated AD mouse models (4-weeks) with a novel formulation of the RyR inhibitor, dantrolene. Using 2-photon Ca2+ imaging and patch clamp recordings, we demonstrate that dantrolene treatment fully normalizes ER Ca2+ signaling within somatic and dendritic compartments in early and later-stage AD mice in hippocampal slices. Additionally, the elevated RyR2 levels in AD mice are restored to control levels with dantrolene treatment, as are synaptic transmission and synaptic plasticity. Aβ deposition within the cortex and hippocampus is also reduced in dantrolene-treated AD mice. In this study, we highlight the pivotal role of Ca2+ aberrations in AD, and propose a novel strategy to preserve synaptic function, and thereby cognitive function, in early AD patients.Keywords
This publication has 48 references indexed in Scilit:
- Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic miceNeuroscience Letters, 2012
- Single-channel Ca2+ imaging implicates Aβ1–42 amyloid pores in Alzheimer’s disease pathologyThe Journal of cell biology, 2011
- Constitutive cAMP response element binding protein (CREB) activation by Alzheimer's disease presenilin-driven inositol trisphosphate receptor (InsP 3 R) Ca 2+ signalingProceedings of the National Academy of Sciences of the United States of America, 2011
- Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's diseaseNeurobiology of Aging, 2011
- Targets for AD treatment: conflicting messages from γ-secretase inhibitorsJournal of Neurochemistry, 2011
- Calcium Signaling and Amyloid Toxicity in Alzheimer DiseaseJournal of Biological Chemistry, 2010
- Gain-of-Function Enhancement of IP 3 Receptor Modal Gating by Familial Alzheimer’s Disease–Linked Presenilin Mutants in Human Cells and Mouse NeuronsScience Signaling, 2010
- Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer diseaseNeurobiology of Aging, 2009
- Dantrolene: Mechanisms of Neuroprotection and Possible Clinical Applications in the Neurointensive Care UnitNeurocritical Care, 2008
- Mechanism of Ca2+ Disruption in Alzheimer's Disease by Presenilin Regulation of InsP3 Receptor Channel GatingNeuron, 2008